- Home
- WSC vs TARS Comparison
WSC vs TARS Comparison
Compare WSC & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WSC | TARS |
|---|---|---|
| Founded | 1944 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WSC | TARS |
|---|---|---|
| Price | $19.87 | $80.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $25.43 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 4.0M | 419.7K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 816.06 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $2,317,990,000.00 | $366,100,000.00 |
| Revenue This Year | N/A | $147.24 |
| Revenue Next Year | N/A | $53.11 |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | N/A | ★ 182.44 |
| 52 Week Low | $14.91 | $38.51 |
| 52 Week High | $39.61 | $85.25 |
Technical Indicators
Market Signals| Indicator | WSC | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 59.14 |
| Support Level | $20.08 | $78.10 |
| Resistance Level | $21.45 | $83.34 |
| Average True Range (ATR) | 0.97 | 3.12 |
| MACD | 0.19 | -0.39 |
| Stochastic Oscillator | 49.94 | 42.64 |
Price Performance
Historical ComparisonAbout WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.